Back to top
more

Celgene Corporation (CELG)

(Delayed Data from NSDQ)

$96.88 USD

96.88
5,654,306

+1.67 (1.75%)

Updated May 3, 2019 04:00 PM ET

After-Market: $96.84 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks News

Celgene (CELG) Beats Q2 Earnings & Sales Estimates, Ups View

Celgene (CELG) reports better-than-expected results for the second-quarter, on the back of growth in Revlimid sales. The company also raises its annual guidance.

    Ekta Bagri headshot

    Celgene (CELG) Beats on Q2 Earnings, Ups View

    Celgene Corporation (CELG) topped on both earnings and sales in the second quarter driven by Revlimid growth. The company also upped its guidance.

      Drug Stocks to Report Earnings on Jul 26: AMGN, ALXN & More

      Let's see how these five pharma/biotech stocks are poised ahead of their scheduled results on Jul 26.

        Celgene (CELG) Q2 Earnings: Disappointment in Store?

        Celgene Corporation (CELG) has been sailing in troubled waters, of late, and the recent pipeline setbacks might weigh on its performance in its second-quarter results.

          Agios (AGIO) Secures FDA Approval for Leukemia Drug Tibsovo

          Agios (AGIO) gains an FDA approval for its lead pipeline candidate, Tibsovo, for the treatment of relapsed/refractory acute myeloid leukemia (AML) in patients with an IDH1 mutation.

            Madhu Goel headshot

            4 Biotech Bets to Watch as Industry Rebounds in a Month

            The biotech sector makes a sharp rise in 30 days post the positive data read out from Biogen's mid-stage Alzheimer's trial on BAN2401. We recommend a few industry players for investors' portfolio boost.

              Celgene Reports Positive Data on Tecentriq, Abraxane Study

              Celgene (CELG) reports positive results from a late-stage study on the combination of oncology drug, Abraxane, with immuno-oncology drug, Tecentriq, in advanced breast cancer patients.

                Biotech Stock Roundup: BIIB's Gain on Alzheimer's Data, Regulatory Updates & More

                Biogen's results from a phase II study in the much-pursued Alzheimer's disease was all over the biotech sector last week.

                  Celgene, Acceleron Report Positive Data on Thalassemia Drug

                  Celgene (CELG) and partner Acceleron Pharma report positive results on luspatercept from a late-stage study. This is the second positive phase III study for the candidate.

                    CTI BioPharma Falls After Failure of Pivotal Lymphoma Study

                    CTI BioPharma (CTIC) and partner Servier announce that a pivotal study evaluating a Pixuvri combination regimen in non-Hodgkin lymphoma fails to improve progression free survival.

                      Sweta Killa headshot

                      Biotech ETFs Surge on Biogen's Positive Drug Trial Result

                      Biotech ETFs surge on Biogen's encouraging Phase 2 clinical study data for Alzheimer???s treatment.

                        Celgene (CELG) Down 21% So Far in 2018: What Lies Ahead?

                        Celgene's (CELG) shares decline 21%, in the year-to-date period, on pipeline setbacks. However, we expect a better performance in the second half.

                          Ryan McQueeney headshot

                          Why Biotech Stocks Rallied on Biogen's Alzheimer's Test

                          Several major biotech stocks rallied on Friday after Biogen (BIIB) reported positive results from a Phase 2 study of its Ban2401 therapy, which seeks to reduce toxic amyloid proteins associated with cognitive decline and Alzheimer's disease.

                            Biotech Stock Roundup: GILD's Positive CHMP Nod, Regulatory Updates & More

                            Key headlines in the biotech sector last week include Gilead getting positive CHMP opinion, Keryx plunging on merger news while Celgene and Amgen came out with pipeline updates.

                              Celgene's Luspatercept Meets Primary Endpoint in the Study

                              Celgene Corporation (CELG) and Acceleron Pharma Inc. (XLRN) announces top-line results from a phase III, multi-center study (MEDALIST), where its pipeline candidate luspatercept met both the primary and secondary endpoints.

                                Sanofi (SNY) Finalizes Deal for European Generic Unit Sale

                                Sanofi (SNY) finalizes sale of its European generic unit, Zentiva, for $2.2 billion.

                                  Ekta Bagri headshot

                                  4 Biotech Stocks to Bet on in the Second Half of 2018

                                  While the first half did not turn out to be great for the biotech sector, the second half is expected to be much better. Here, we list four biotechs poised for a good run.

                                    Agios Out-Licenses China Rights to Leukemia Drug Tibsovo

                                    Agios (AGIO) and CStone Pharmaceticals sign an exclusive collaboration and license agreement for the development and commercialization of its lead pipeline candidate Tibsovo.

                                      Zacks Value Investor Highlights: Gilead Sciences, Biogen, Celgene, Lannett and Valeant

                                      Zacks Value Investor Highlights: Gilead Sciences, Biogen, Celgene, Lannett and Valeant

                                        Tracey Ryniec headshot

                                        Drug Stocks: The Next Hot Industry or Value Traps?

                                        These 5 stocks look dirt cheap but is it too good to be true?

                                          Amgen Gets FDA Nod to Add ASPIRE Data on Kyprolis Label

                                          Amgen (AMGN) gets FDA approval to add overall survival data from the phase III ASPIRE study on the label of its multiple myeloma drug, Kyprolis.

                                            Alexion-Complement Pharma Tie Up to Treat Neuro Disorders

                                            Alexion (ALXN) teams up with Complement Pharma to co-develop its C6 inhibitor, CP010, for neurodegenerative disorders.

                                              Mark Vickery headshot

                                              Top Research Reports for Disney, Caterpillar & MetLife

                                              Today's Research Daily features new research reports on 16 major stocks, including Disney (DIS), Caterpillar (CAT) and MetLife (MET).

                                                Biotech Stock Roundup: Regeneron, Celgene, Amgen Impress at ASCO

                                                The biotech sector was in focus last week due to the ASCO meet at Chicago where biotech bigwigs presented data on their oncology drugs and promising pipeline candidates.

                                                  Celgene Presents Data on CAR T Therapy, Revlimid & Pomalyst

                                                  Biotech major Celgene presents encouraging data on its oncology drugs Revlimid, Pomalyst along with other experimental therapies at the ASCO.